(1→3)-β-d-glucan in cerebrospinal fluid as a biomarker for Candida and Aspergillus infections of the central nervous system in pediatric patients

Christine M. Salvatore, Tempe K. Chen, Sima S. Toussi, Patricia DeLaMora, Ruta Petraitiene, Malcolm A. Finkelman, Thomas J. Walsh

Research output: Research - peer-reviewArticle

Abstract

Background: Fungal infections of the central nervous system (FICNS) are important causes of morbidity and mortality among immunocompromised pediatric patients. Standard diagnostic modalities lack the sensitivity for detecting and therapeutically monitoring these life-threatening diseases. Current molecular methods remain investigational. (1→3)-β-d-glucan (BDG) is a cell wall component found in several fungal pathogens, including Candida and Aspergillus spp. Detecting BDG in cerebrospinal fluid (CSF) may be an important approach for detecting and therapeutically monitoring FICNS. To date, there has been no study that has investigated the effectiveness of CSF BDG as a diagnostic and therapeutic marker of FICNS in children. Methods: Serial BDG levels were measured in serum and CSF samples obtained from pediatric patients (aged 0-18 years) with a diagnosis of probable or proven Candida or Aspergillus CNS infection. Results: Nine cases of FICNS were identified in patients aged 1 month to 18 years. Two patients were infected with an Aspergillus species, and 7 patients were infected with a Candida species. All the patients at baseline had detectable BDG in their CSF. Among 7 patients who completed therapy for an FICNS, all elevated CSF BDG levels decreased to <31 pg/mL. At the time of this writing, 1 patient was still receiving therapy and continued to have elevated BDG levels. One patient died from overwhelming disseminated candidiasis. The lengths of therapy for these 9 children ranged from 2 weeks to 28 months. Conclusion: The BDG assay is useful in diagnosing and therapeutically monitoring Candida and Aspergillus CNS infections in pediatric patients.

LanguageEnglish (US)
Article numberpiv014
Pages277-286
Number of pages10
JournalJournal of the Pediatric Infectious Diseases Society
Volume5
Issue number3
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Central Nervous System Infections
beta-Glucans
Aspergillus
Candida
Cerebrospinal Fluid
Biomarkers
Pediatrics
Central Nervous System Fungal Infections
Therapeutics
Infection
Candidiasis
Immunocompromised Host
Cellular Structures
Cell Wall
Morbidity
Mortality
Serum

Keywords

  • (1→3)-β-d-glucan
  • Central nervous system
  • Children
  • Fungal infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Salvatore, C. M., Chen, T. K., Toussi, S. S., DeLaMora, P., Petraitiene, R., Finkelman, M. A., & Walsh, T. J. (2016). (1→3)-β-d-glucan in cerebrospinal fluid as a biomarker for Candida and Aspergillus infections of the central nervous system in pediatric patients. Journal of the Pediatric Infectious Diseases Society, 5(3), 277-286. [piv014]. DOI: 10.1093/jpids/piv014

(1→3)-β-d-glucan in cerebrospinal fluid as a biomarker for Candida and Aspergillus infections of the central nervous system in pediatric patients. / Salvatore, Christine M.; Chen, Tempe K.; Toussi, Sima S.; DeLaMora, Patricia; Petraitiene, Ruta; Finkelman, Malcolm A.; Walsh, Thomas J.

In: Journal of the Pediatric Infectious Diseases Society, Vol. 5, No. 3, piv014, 01.09.2016, p. 277-286.

Research output: Research - peer-reviewArticle

Salvatore, Christine M. ; Chen, Tempe K. ; Toussi, Sima S. ; DeLaMora, Patricia ; Petraitiene, Ruta ; Finkelman, Malcolm A. ; Walsh, Thomas J./ (1→3)-β-d-glucan in cerebrospinal fluid as a biomarker for Candida and Aspergillus infections of the central nervous system in pediatric patients. In: Journal of the Pediatric Infectious Diseases Society. 2016 ; Vol. 5, No. 3. pp. 277-286
@article{d8844685cdec4d15ad4ca4a09c8efe5b,
title = "(1→3)-β-d-glucan in cerebrospinal fluid as a biomarker for Candida and Aspergillus infections of the central nervous system in pediatric patients",
abstract = "Background: Fungal infections of the central nervous system (FICNS) are important causes of morbidity and mortality among immunocompromised pediatric patients. Standard diagnostic modalities lack the sensitivity for detecting and therapeutically monitoring these life-threatening diseases. Current molecular methods remain investigational. (1→3)-β-d-glucan (BDG) is a cell wall component found in several fungal pathogens, including Candida and Aspergillus spp. Detecting BDG in cerebrospinal fluid (CSF) may be an important approach for detecting and therapeutically monitoring FICNS. To date, there has been no study that has investigated the effectiveness of CSF BDG as a diagnostic and therapeutic marker of FICNS in children. Methods: Serial BDG levels were measured in serum and CSF samples obtained from pediatric patients (aged 0-18 years) with a diagnosis of probable or proven Candida or Aspergillus CNS infection. Results: Nine cases of FICNS were identified in patients aged 1 month to 18 years. Two patients were infected with an Aspergillus species, and 7 patients were infected with a Candida species. All the patients at baseline had detectable BDG in their CSF. Among 7 patients who completed therapy for an FICNS, all elevated CSF BDG levels decreased to <31 pg/mL. At the time of this writing, 1 patient was still receiving therapy and continued to have elevated BDG levels. One patient died from overwhelming disseminated candidiasis. The lengths of therapy for these 9 children ranged from 2 weeks to 28 months. Conclusion: The BDG assay is useful in diagnosing and therapeutically monitoring Candida and Aspergillus CNS infections in pediatric patients.",
keywords = "(1→3)-β-d-glucan, Central nervous system, Children, Fungal infection",
author = "Salvatore, {Christine M.} and Chen, {Tempe K.} and Toussi, {Sima S.} and Patricia DeLaMora and Ruta Petraitiene and Finkelman, {Malcolm A.} and Walsh, {Thomas J.}",
year = "2016",
month = "9",
doi = "10.1093/jpids/piv014",
volume = "5",
pages = "277--286",
journal = "Journal of the Pediatric Infectious Diseases Society",
issn = "2048-7207",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - (1→3)-β-d-glucan in cerebrospinal fluid as a biomarker for Candida and Aspergillus infections of the central nervous system in pediatric patients

AU - Salvatore,Christine M.

AU - Chen,Tempe K.

AU - Toussi,Sima S.

AU - DeLaMora,Patricia

AU - Petraitiene,Ruta

AU - Finkelman,Malcolm A.

AU - Walsh,Thomas J.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background: Fungal infections of the central nervous system (FICNS) are important causes of morbidity and mortality among immunocompromised pediatric patients. Standard diagnostic modalities lack the sensitivity for detecting and therapeutically monitoring these life-threatening diseases. Current molecular methods remain investigational. (1→3)-β-d-glucan (BDG) is a cell wall component found in several fungal pathogens, including Candida and Aspergillus spp. Detecting BDG in cerebrospinal fluid (CSF) may be an important approach for detecting and therapeutically monitoring FICNS. To date, there has been no study that has investigated the effectiveness of CSF BDG as a diagnostic and therapeutic marker of FICNS in children. Methods: Serial BDG levels were measured in serum and CSF samples obtained from pediatric patients (aged 0-18 years) with a diagnosis of probable or proven Candida or Aspergillus CNS infection. Results: Nine cases of FICNS were identified in patients aged 1 month to 18 years. Two patients were infected with an Aspergillus species, and 7 patients were infected with a Candida species. All the patients at baseline had detectable BDG in their CSF. Among 7 patients who completed therapy for an FICNS, all elevated CSF BDG levels decreased to <31 pg/mL. At the time of this writing, 1 patient was still receiving therapy and continued to have elevated BDG levels. One patient died from overwhelming disseminated candidiasis. The lengths of therapy for these 9 children ranged from 2 weeks to 28 months. Conclusion: The BDG assay is useful in diagnosing and therapeutically monitoring Candida and Aspergillus CNS infections in pediatric patients.

AB - Background: Fungal infections of the central nervous system (FICNS) are important causes of morbidity and mortality among immunocompromised pediatric patients. Standard diagnostic modalities lack the sensitivity for detecting and therapeutically monitoring these life-threatening diseases. Current molecular methods remain investigational. (1→3)-β-d-glucan (BDG) is a cell wall component found in several fungal pathogens, including Candida and Aspergillus spp. Detecting BDG in cerebrospinal fluid (CSF) may be an important approach for detecting and therapeutically monitoring FICNS. To date, there has been no study that has investigated the effectiveness of CSF BDG as a diagnostic and therapeutic marker of FICNS in children. Methods: Serial BDG levels were measured in serum and CSF samples obtained from pediatric patients (aged 0-18 years) with a diagnosis of probable or proven Candida or Aspergillus CNS infection. Results: Nine cases of FICNS were identified in patients aged 1 month to 18 years. Two patients were infected with an Aspergillus species, and 7 patients were infected with a Candida species. All the patients at baseline had detectable BDG in their CSF. Among 7 patients who completed therapy for an FICNS, all elevated CSF BDG levels decreased to <31 pg/mL. At the time of this writing, 1 patient was still receiving therapy and continued to have elevated BDG levels. One patient died from overwhelming disseminated candidiasis. The lengths of therapy for these 9 children ranged from 2 weeks to 28 months. Conclusion: The BDG assay is useful in diagnosing and therapeutically monitoring Candida and Aspergillus CNS infections in pediatric patients.

KW - (1→3)-β-d-glucan

KW - Central nervous system

KW - Children

KW - Fungal infection

UR - http://www.scopus.com/inward/record.url?scp=84995701386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995701386&partnerID=8YFLogxK

U2 - 10.1093/jpids/piv014

DO - 10.1093/jpids/piv014

M3 - Article

VL - 5

SP - 277

EP - 286

JO - Journal of the Pediatric Infectious Diseases Society

T2 - Journal of the Pediatric Infectious Diseases Society

JF - Journal of the Pediatric Infectious Diseases Society

SN - 2048-7207

IS - 3

M1 - piv014

ER -